Comparing the current results to its competitors, Viracta Therapeutics Inc reported Revenue decrease in the 3 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.45 %, recorded in the same quarter.
Viracta Therapeutics Inc , slower than the average decrease reported by the company's competitors of -47.17 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -47.17 %
Viracta Therapeutics Inc 's Comment on Competition and Industry Peers
Viracta operates within the pharmaceutical and biotechnology industries, which are characterized by rapid technological advancement and significant competition. The company identifies its technology, expertise, research, clinical capabilities, development experience, and scientific knowledge as competitive advantages. Viracta faces competition from pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. Competitors often possess greater financial resources, established market presence, and expertise in research and development, manufacturing, nonclinical testing, clinical trials, regulatory approvals, reimbursement, and marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger companies. Mergers and acquisitions may further concentrate resources among competitors. Viracta's commercial potential could be diminished if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient, or are less expensive.
January 4, 2024
Viracta Therapeutics: Advancing a Promising Treatment for Relapsed or Refractory EBV Peripheral T-cell Lymphoma Viracta Therapeutics, a leading clinical-stage biotechnology company, has provided an update on the progress of its innovative treatment, Nana-val, for patients with relapsed or refractory Epstein-Barr Virus (EBV) peripheral T-cell lymphoma. The company announced the successful completion of Stage 1 enrollment and anticipates complete enrollment of Stage 2 in the first quarter of 2024. Furthermore, Viracta Therapeutics is actively engaging with the FDA to explore the possibility of an accelerated approval pathway by mid-2024. This news comes in conjunction with the company s previous announcement o...
In a significant breakthrough for the field of cancer therapeutics, Viracta Therapeutics has recently announced that the United States Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for their groundbreaking drug, Nana-val, in the treatment of nasopharyngeal carcinoma (NPC). This distinction is notable as it marks the first time Nana-val has received orphan drug designation for Epstein-Barr virus (EBV) and solid tumors, ushering in a new era in combating these challenging medical conditions. Nasopharyngeal carcinoma is a rare form of cancer that affects the nasopharynx, the uppermost part of the throat behind the nose. It is notoriously difficult to treat due ...
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Ayala Pharmaceuticals Inc is a biopharmaceutical company focused on developing targeted therapies for patients with rare and aggressive cancers. Their business model revolves around leveraging scientific expertise and strategic partnerships to advance their pipeline of potential treatments and ultimately bring them to market.
Arbutus Biopharma Corp is a biopharmaceutical company focused on discovering and developing innovative therapies for patients suffering from Hepatitis B. They aim to utilize their proprietary technologies to both advance their internal pipeline and collaborate with partners to develop a cure for Hepatitis B. Their business model revolves around leveraging their expertise and strategic partnerships to create effective treatments that address the unmet needs of Hepatitis B patients.
Sources:
Viracta Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Viracta Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
